Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVAMUNE Safety and Immunogenicity in Healthy Adults
NCT01827371Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2013
- Primary completion
- Apr 2015
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of JYNNEOS in smallpox, sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2013; status: completed.
02
Drugs
JYNNEOS
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT01827371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827371.